Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://link.springer.com/doi/10.1007/s00702-016-1597-3 below:

Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer’s disease and in mild cognitive impairment due to AD

Synaptic dysfunction is linked to both major depressive disorder (MDD) and Alzheimer’s disease (AD). Synapse protein concentrations in cerebrospinal fluid (CSF) may be useful biomarkers to monitor synaptic dysfunction and degeneration that lead to depressive symptoms and AD, respectively. CSF neurogranin (Ng), a post-synaptic protein, has emerged as a promising tool to measure synaptic dysfunction and/or loss in AD. The aim of this study was to test the specific hypothesis that CSF neurogranin (Ng) is able to differentiate AD from MDD and cognitively normal controls. CSF samples from 44 healthy control individuals (CTRL), 86 patients with mild cognitive impairment (MCI), 36 of whom had prodromal AD as defined by a positive CSF AD biomarker signature, 25 AD dementia and 6 patients with MDD were analysed using an in house enzyme-linked immunosorbent assay for Ng. CSF Ng levels were significantly higher in AD patients and in prodromal AD (MCI patients with an “AD-like” CSF tau and Aβ42 profile) compared with CTRL individuals (p < 0.0001 for both groups) and MDD patients (p < 0.001 and p < 0.01, respectively). Significantly higher CSF Ng concentration was also seen in prodromal AD patients as compared to MCI patients without biomarker evidence of underlying AD pathology (p < 0.0001). CSF Ng correlated positively with the classical axonal injury markers CSF T-tau and P-tau (p < 0.0001), whereas correlation to plaque pathology as reflected by CSF Aβ42 was less clear. Negative correlations of CSF Ng with cognitive evaluation scores (MMSE and CAMCOG) were observed. This study strengthens the clinical utility of CSF Ng as a CSF biomarker for AD. AD patients in both MCI and dementia stages of the disease had increased CSF Ng concentrations compared with cognitively normal control individuals, patients with non-AD MCI and patients with MDD. The lowest CSF Ng concentrations were seen in patients with MDD, a finding that warrants validation in further studies.

This is a preview of subscription content, log in via an institution to check access.

Springer+ Basic

€34.99 /Month

• Get 10 units per month
• Download Article/Chapter or eBook
• 1 Unit = 1 Article or 1 Chapter
• Cancel anytime

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

AD:

Alzheimer’s disease

Aβ:

Amyloid-β

CAMCOG:

Cambridge cognition examination

CSF:

Cerebrospinal fluid

CTRL:

Healthy control

MCI:

Mild cognitive impairment

MDD:

Major depression disorders

MMSE:

Mini Mental State Examination

Ng:

Neurogranin

P-tau:

Hyperphosphorylated tau

T-tau:

Total tau

• American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington DC. doi:10.1176/appi.books.9780890425596

• American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn (text rev.). American Psychiatric Association, Arlington. doi:10.1176/appi.books.9780890423349

• Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6(3):131–144. doi:10.1038/nrneurol.2010.4

  Article  CAS  PubMed  Google Scholar 

• De Vos A, Jacobs D, Struyfs H, Fransen E, Andersson K, Portelius E, Andreasson U, De Surgeloose D, Hernalsteen D, Sleegers K, Robberecht C, Van Broeckhoven C, Zetterberg H, Blennow K, Engelborghs S, Vanmechelen E (2015) C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer’s disease. Alzheimers Dement 11(12):1461–1469. doi:10.1016/j.jalz.2015.05.012

  Article  PubMed  Google Scholar 

• DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 27(5):457–464. doi:10.1002/ana.410270502

  Article  CAS  PubMed  Google Scholar 

• Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338(6103):68–72. doi:10.1126/science.1222939

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198

  Article  CAS  PubMed  Google Scholar 

• Hamilton MA (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, Blennow K, Kornhuber J, Maler JM, Zetterberg H, Spitzer P (2015) Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease. Alzheimers Res Ther 7(1):74. doi:10.1186/s13195-015-0161-y

  Article  PubMed  PubMed Central  Google Scholar 

• Janelidze S, Hertze J, Zetterberg H, Landqvist Waldo M, Santillo A, Blennow K, Hansson O (2016) Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Ann Clin Transl Neurol 3(1):12–20. doi:10.1002/acn3.266

  Article  CAS  PubMed  Google Scholar 

• Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM (2015) Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic alzheimer disease. JAMA Neurol 72(11):1275–1280. doi:10.1001/jamaneurol.2015.1867

  Article  PubMed  PubMed Central  Google Scholar 

• Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, Hansson O, Andreasson U, Teunissen CE, Scheltens P, Van der Flier WM, Zetterberg H, Portelius E, Blennow K (2015a) Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimer’s Dement J Alzheimer’s Assoc 11(10):1180–1190. doi:10.1016/j.jalz.2014.10.009

  Article  Google Scholar 

• Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N, Kornhuber J, Hansson O, Minthon L, Spitzer P, Maler JM, Zetterberg H, Blennow K, Lewczuk P (2015b) Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls. Alzheimers Res Ther 7(1):40. doi:10.1186/s13195-015-0124-3

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939–944

  Article  CAS  PubMed  Google Scholar 

• Portelius E, Zetterberg H, Skillback T, Tornqvist U, Andreasson U, Trojanowski JQ, Weiner MW, Shaw LM, Mattsson N, Blennow K, Alzheimer’s Disease Neuroimaging I (2015) Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease. Brain 138(Pt 11):3373–3385. doi:10.1093/brain/awv267

  Article  PubMed  PubMed Central  Google Scholar 

• Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R (1986) CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149:698–709

  Article  CAS  PubMed  Google Scholar 

• Tarawneh R, D’Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris JC, Holtzman DM (2016) Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol. doi:10.1001/jamaneurol.2016.0086

  PubMed  Google Scholar 

• Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, Hansson O, Minthon L, Zetterberg H, Blennow K (2010) Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer’s disease. Brain Res 1362:13–22. doi:10.1016/j.brainres.2010.09.073

  Article  CAS  PubMed  Google Scholar 

• Wellington H, Paterson RW, Portelius E, Tornqvist U, Magdalinou N, Fox NC, Blennow K, Schott JM, Zetterberg H (2016) Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. doi:10.1212/WNL.0000000000002423

  PubMed  PubMed Central  Google Scholar 

• Yin J, Samawi H, Linder D (2016) Improved nonparametric estimation of the optimal diagnostic cut-off point associated with the Youden index under different sampling schemes. Biom J. doi:10.1002/bimj.201500036

  PubMed  Google Scholar 

Download references

1. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

   Cristina Sanfilippo, Henrik Zetterberg & Kaj Blennow

2. Section of Neurosciences, Department G.F. Ingrassia, University of Catania, Via Santa Sofia, 78, 95123, Catania, Italy

   Cristina Sanfilippo

3. Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, University of São Paulo, São Paulo, Brazil

   Orestes Forlenza

4. Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK

   Henrik Zetterberg

1. Cristina Sanfilippo
2. Orestes Forlenza
3. Henrik Zetterberg
4. Kaj Blennow

Correspondence to Cristina Sanfilippo.

Sanfilippo, C., Forlenza, O., Zetterberg, H. et al. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer’s disease and in mild cognitive impairment due to AD. J Neural Transm 123, 1443–1447 (2016). https://doi.org/10.1007/s00702-016-1597-3

Download citation

• Received: 16 April 2016

• Accepted: 18 July 2016

• Published: 16 August 2016

• Issue Date: December 2016

• DOI: https://doi.org/10.1007/s00702-016-1597-3

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.4